Gene therapy of melanoma pulmonary metastasis by intramuscular injection of plasmid DNA encoding tissue inhibitor of metalloproteinases-1.
Tumor cell invasion and metastasis are a complex multistep process that involves the degradation of extracellular matrix proteins by matrix metalloproteinases. Tissue inhibitor of metalloproteinase-1 (TIMP-1) acts as a negative regulator of matrix metalloproteinases and thus prevents tumor cell invasion and metastasis by preserving extracellular matrix integrity. In the present study, we investigated whether increasing serum TIMP-1 levels by gene transfer would decrease experimental pulmonary metastasis of melanoma in C57BL/6 mice. Female animals bearing B16F10 melanoma pulmonary metastasis were injected intramuscularly twice per week with 100 microg of plasmid DNA encoding the human TIMP-1 cDNA (TIMP-1pDNA). Substantive levels of serum human TIMP-1 were observed 3 days after single injection and were found for 6 days thereafter. Pulmonary metastasis was significantly reduced in the mice following 4 weeks of TIMP-1 treatment as compared to the controls that were treated with the plasmid DNA vector alone. Further reduction of pulmonary metastasis and increase in survival were realized by intraperitoneal injection of 1000 U of IL-2 twice per week in combination with TIMP-1 treatment. In a parallel in vitro study, a 3-fold increase in TIMP-1 expression was observed in NIH3T3 cells after IL-2 treatment. Therefore, up-regulation of TIMP-1 expression by IL-2 likely contributed to the additive effect of IL-2 and TIMP-1 in reducing metastatic disease in the animal model. In conclusion, our findings support the potential of TIMP-1 gene therapy for the prevention of metastatic melanoma.
Shi
Yufei
Y
Department of Biological and Medical Research, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia. yufei@kfshrc.edu.sa
Parhar
Ranjit S
RS
Zou
Minjing
M
Al-Mohanna
Futwan A
FA
Paterson
Malcolm C
MC
D000818:Animals; D002478:Cells, Cultured; D016207:Cytokines / Q000378:metabolism / Q000494:pharmacology; D004247:DNA / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D015316:Genetic Therapy; D006801:Humans; D007273:Injections, Intramuscular; D007375:Interleukin-1 / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000201:enzymology / Q000556:secondary / Q000628:therapy*; D008546:Melanoma, Experimental / Q000201:enzymology / Q000556:secondary / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D009361:Neoplasm Invasiveness; D010957:Plasmids / Q000235:genetics*; D011480:Protease Inhibitors / Q000097:blood; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood / Q000235:genetics*; D014162:Transfection
D016207:Cytokines; D007375:Interleukin-1; D011480:Protease Inhibitors; D019715:Tissue Inhibitor of Metalloproteinase-1; D004247:DNA